Loading…
← CockpitCompetitor Analysis › 688185.SS CanSino Biologics, Inc. Class AOpen in the cockpit ↗

CanSino Biologics, Inc. Class A688185.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese biopharma known for its adenovirus-vector COVID-19 vaccine and other vaccines including meningitis and Ebola.

≈ China's answer to a viral-vector vaccine developer like J&J's Janssen unitMomentum leader 84
Mkt cap
$1.38B
US dollars, full cap
Free float
16%
of shares outstanding
$/day
$81.2M
20-day average traded
Fwd P/E
199.3×
forward earnings
ROIC−WACC
-9.5 pp
WACC 11.2%
Hurdle
n/a
no reverse DCF
Next earnings
132 days
30 Mar 2027
Close · CNYCN¥60.16
1D-0.7%
1W-20.8%
1M-24.0%
3M+6.1%
6M+0.3%
YTD-4.3%
1Y-21.6%
ATR %9.2%
52w lowhigh44.3% off high

What CanSino Biologics does

Chinese biopharma known for its adenovirus-vector COVID-19 vaccine and other vaccines including meningitis and Ebola.

Most of its non-COVID vaccines are sold on China's voluntary market, where people pay themselves via local disease-control centres rather than through state-funded programmes, so uptake depends on marketing and perceived need. COVID vaccine sales were once large but faded after the pandemic peak.

In one line: China's answer to a viral-vector vaccine developer like J&J's Janssen unit.

Products and services

  • Adenovirus-vector COVID-19 vaccine (Convidecia)
  • Meningococcal vaccines
  • Ebola vaccine
  • Pipeline combination/mRNA vaccines

Customers

  • CDC/vaccination programs
  • Government stockpiling programs
  • Export markets

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Vaccines

What could go right

  • Vaccine export demand
  • New vaccine pipeline approvals

What could go wrong

  • Post-pandemic COVID vaccine demand collapse
  • R&D cash burn

Moat: narrow (IP / patents, regulatory licence). Proprietary adenovirus-vector platform and one of few Chinese firms with an approved viral-vector vaccine.

Headquarters: Tianjin, China · Employees: 1,134

Named competitors

CanSino Biologics at a glance

Size CanSino Biologics (688185.SS) is a China Health Care company (Biotechnology) with a market value of $1.38B, the 1634th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥60.16 on 18 Nov 2026.

Performance Over six months the shares gained 0.3%, against -18.9% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 19 in its peer set.

Growth Revenue grew 29.9% over the last twelve months (peer median +24.8%); the operating margin is -4.2% (peer median -296.1%).

Valuation It trades at 199.3× forward earnings against a peer median of 46.4× (most expensive of 6).

Capital Return on invested capital runs 9.5 points below its cost of capital (11.2% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026688185.SS 96Peer median 79
Six months, rebased to 100: CanSino Biologics against the median of its 20 peers (local-currency closes).

CanSino Biologics financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.26BCN¥1.07BCN¥836MCN¥349MCN¥1.03B
Revenue growth—+28%+139%-66%—
Gross profitCN¥1.03BCN¥729MCN¥517M-CN¥21.8MCN¥536M
EBITDAn/aCN¥65.5M-CN¥185M-CN¥1.54B-CN¥1.32B
Net incomeCN¥29.7MCN¥27.9M-CN¥379M-CN¥1.48B-CN¥909M
Free cash flow-CN¥60.9M-CN¥108M-CN¥536M-CN¥1.47B-CN¥2.82B
Capital expenditureCN¥159MCN¥244MCN¥458MCN¥610MCN¥1.08B
Total debtCN¥930MCN¥1.29BCN¥2.02BCN¥2.71BCN¥2.73B

Quarterly statements and history in the cockpit →

CanSino Biologics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%+50%4588NTLARAPPTYRAANABABSINUVBQURE688105NVAX688765MSB087010688185.SS6-month return →1-month return →
Up and to the right = strong over both horizons. CanSino Biologics is the large dot.

Fundamentals: revenue growth against valuation

0%+100%0×100×200×ANAB688105NVAXURGN2637688185.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CanSino Biologics is the large dot.

CanSino Biologics competitors and peer comparison

Head to head with its named competitors (688185.SS vs 300142.SZ vs JNJ vs 300122.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
CanSino Biologics 688185.SS$1.38B0%+30%-4%199.3×n/a
Walvax Biotechnology 300142.SZ$2.48B-26%-23%5%348.7×29.5%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
Chongqing Zhifei Biological Products 300122.SZ$5.28B-1%-28%-210%n/a-6.5%

How CanSino Biologics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CanSino Biologics against its 20 peers (data as of 18 Nov 2026)
Measure688185.SSPeer medianRank in peer set
1-month return-24.0%-14.8%2nd lowest of 21
6-month return+0.3%-18.9%4th highest of 19
Distance from 52-week high-44.3%-47.0%9th highest of 21
Revenue growth (TTM)+29.9%+24.8%8th highest of 18
Operating margin-4.2%-296.1%3rd highest of 19
Forward P/E199.3×46.4×most expensive of 6
ROIC minus cost of capital-9.5 pp-23.7 pp3rd highest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%199.3×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%n/an/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%n/an/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%n/an/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%4.9×0.5%+25.6%
Absci ABSIUnited States$1.41B+65%-47%-9,155%n/an/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%n/an/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%n/an/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%n/an/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%137.8×39.4%-2.5%
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%n/an/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%n/an/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%134.6×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%n/an/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%n/an/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%16.7×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%46.4×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%n/an/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%n/an/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a

Questions

Who are CanSino Biologics's main competitors?
Named competitors: Walvax Biotechnology (300142.SZ), Johnson & Johnson (JNJ), Chongqing Zhifei Biological Products (300122.SZ). The cockpit's measured peer set (industry) also includes Oncolys BioPharma (4588.T), Intellia Therapeutics (NTLA), Rapport Therapeutics (RAPP), Tyra Bioscience (TYRA), AnaptysBio (ANAB), Absci (ABSI).
Is CanSino Biologics expensive compared with its peers?
On forward p/e it trades at 199.3× against a peer median of 46.4×, most expensive of 6 in its peer set.
How has CanSino Biologics stock performed?
Over six months to 18 Nov 2026 the shares returned +0.3% against -18.9% for the median peer; over one year -21.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.